Information Provided By: 
Fly News Breaks for June 27, 2018
AQXP
Jun 27, 2018 | 12:24 EDT
As previously reported, Cantor Fitzgerald analyst William Tanner downgraded Aquinox Pharmaceuticals to Neutral from Overweight and lowered his price target on the stock to $2 from $28 following the announcement of the failure of the LEADERSHIP-301 trial. Given the decision to discontinue all rosiptor development, the company has little value other than cash, said Tanner. In early afternoon trading, Aquinox shares are down $12.77, or 83%, to $2.54.
News For AQXP From the Last 2 Days
There are no results for your query AQXP
